A review on potential of PARP inhibitors in the treatment of prostate cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.
| Glavni avtor: | |
|---|---|
| Drugi avtorji: | |
| Format: | Thesis |
| Jezik: | English |
| Izdano: |
Brac University
2022
|
| Teme: | |
| Online dostop: | http://hdl.handle.net/10361/17308 |
| id |
10361-17308 |
|---|---|
| record_format |
dspace |
| spelling |
10361-173082022-09-26T21:02:06Z A review on potential of PARP inhibitors in the treatment of prostate cancer Islam, Saidul Sharmin, Shahana Department of Pharmacy, Brac University Prostate cancer Therapeutic approaches mCRPC PARP inhibitors Olaparib Cancer--Treatment Enzyme inhibitors--Therapeutic use Cancer--Gene therapy This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. Cataloged from PDF version of thesis report. Includes bibliographical references (pages 33-39). Prostate cancer is still a fatal disease at metastatic castration resistance stage (mCRPC) in spite of pursuing advancements in patient survival, indicating the necessity of therapeutic approaches. A significant number of individuals having advanced prostate cancer, most of whom have a poor prognosis, have germinal and/or somatic mutations in their DNA damage response genes. These kinds of mutations lead to a reliance on the Poly (adenosine diphosphate ribose) polymerase for repairing single-strand breaks, indicating the necessity of Poly ADP Ribose Polymerase (PARP) inhibitors. Olaparib was the first FDA approved PARP inhibitor to demonstrate the improved overall survival in mCRPC patients having homologous recombination repair defects. Despite the fact that this is a significant step forward, there are still a number of questions regarding PARP inhibitors. This paper aims to discuss the significance and efficacy of PARP inhibitors mentioning the associated challenges and their future in the treatment of prostate cancer. Saidul Islam B. Pharmacy 2022-09-26T06:17:43Z 2022-09-26T06:17:43Z 2022 2022-05 Thesis ID 18146010 http://hdl.handle.net/10361/17308 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 39 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Prostate cancer Therapeutic approaches mCRPC PARP inhibitors Olaparib Cancer--Treatment Enzyme inhibitors--Therapeutic use Cancer--Gene therapy |
| spellingShingle |
Prostate cancer Therapeutic approaches mCRPC PARP inhibitors Olaparib Cancer--Treatment Enzyme inhibitors--Therapeutic use Cancer--Gene therapy Islam, Saidul A review on potential of PARP inhibitors in the treatment of prostate cancer |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. |
| author2 |
Sharmin, Shahana |
| author_facet |
Sharmin, Shahana Islam, Saidul |
| format |
Thesis |
| author |
Islam, Saidul |
| author_sort |
Islam, Saidul |
| title |
A review on potential of PARP inhibitors in the treatment of prostate cancer |
| title_short |
A review on potential of PARP inhibitors in the treatment of prostate cancer |
| title_full |
A review on potential of PARP inhibitors in the treatment of prostate cancer |
| title_fullStr |
A review on potential of PARP inhibitors in the treatment of prostate cancer |
| title_full_unstemmed |
A review on potential of PARP inhibitors in the treatment of prostate cancer |
| title_sort |
review on potential of parp inhibitors in the treatment of prostate cancer |
| publisher |
Brac University |
| publishDate |
2022 |
| url |
http://hdl.handle.net/10361/17308 |
| work_keys_str_mv |
AT islamsaidul areviewonpotentialofparpinhibitorsinthetreatmentofprostatecancer AT islamsaidul reviewonpotentialofparpinhibitorsinthetreatmentofprostatecancer |
| _version_ |
1814307276166529024 |